Arrowhead Pharmaceuticals' 15min chart triggers Bollinger Bands expanding upward, KDJ golden cross.

Arrowhead Pharmaceuticals's 15-minute chart has exhibited an upward trend, as evidenced by the expansion of Bollinger Bands and the KDJ Golden Cross on August 20, 2025, at 15:00. This indicates that the market trend is being driven by strong buying momentum, with a shift towards an upward momentum and potential for further price increases.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has experienced a significant uptick in its stock price, climbing 24.9 percent week-on-week as of August 19, 2025. This substantial increase can be attributed to the company receiving $100 million in payments from Sarepta Therapeutics, Inc. (NASDAQ: SRPT) in relation to a licensing agreement [1]. The payment was made in satisfaction of Arrowhead Pharmaceuticals' achievement of the first of two pre-specified enrollment targets in an early-stage clinical trial for ARO-DM1, a therapy candidate for type 1 myotonic dystrophy (DM1).

Of the $100 million, Arrowhead Pharmaceuticals received $50 million in cash and $50 million in shares, which were subsequently placed into the treasury. This move effectively reduced the company's outstanding shares, thereby boosting the value of existing shares. Arrowhead Pharmaceuticals' President and CEO, Christopher Anzalone, expressed optimism about the company's progress and the potential benefits of reducing outstanding shares [1].

The stock's recent performance has been supported by strong market indicators. On August 20, 2025, at 15:00, Arrowhead Pharmaceuticals' 15-minute chart exhibited an upward trend, as evidenced by the expansion of Bollinger Bands and the KDJ Golden Cross. These indicators suggest that the market trend is being driven by strong buying momentum, with a shift towards an upward momentum and potential for further price increases [2].

Analysts have also provided positive forecasts for Arrowhead Pharmaceuticals' stock. According to StockInvest.us, the stock is expected to rise by 11.48 percent during the next three months, with a 90 percent probability of holding a price between $17.20 and $22.94 at the end of this period [2]. Additionally, Sarepta Therapeutics plans to sell 9.3 million Arrowhead Pharmaceuticals shares, aiming to raise at least $174 million. Analysts predict a potential upside of 54.59 percent for Sarepta's stock price, with a one-year target of $31.54 [3].

Despite these positive indicators, investors should remain cautious and conduct thorough research before making investment decisions. The biotech sector is known for its volatility, and Arrowhead Pharmaceuticals' stock is no exception. The company's success in clinical trials and its collaboration with Sarepta Therapeutics are promising, but the stock's performance may be influenced by various factors, including regulatory approvals, market conditions, and competition in the biotech space.

References:

[1] https://finance.yahoo.com/news/arrowhead-arwr-climbs-24-9-163154134.html
[2] https://stockinvest.us/stock/ARWR
[3] https://www.ainvest.com/news/sarepta-therapeutics-raises-174-million-selling-arrowhead-pharmaceuticals-shares-analysts-predict-significant-upside-stock-price-2508/